# Combination of ETV, TQ-A3334 and TQ-B2450 for CHB (Neptune Study)

> **NCT04202653** · PHASE2 · UNKNOWN · sponsor: **Tongji Hospital** · enrollment: 30 (estimated)

## Conditions studied

- Chronic Hepatitis b

## Interventions

- **DRUG:** ETV
- **DRUG:** TQ-A3334
- **DRUG:** TQ-B2450

## Key facts

- **NCT ID:** NCT04202653
- **Lead sponsor:** Tongji Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-01-01
- **Primary completion:** 2020-12-31
- **Final completion:** 2021-06-30
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2019-12-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04202653

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04202653, "Combination of ETV, TQ-A3334 and TQ-B2450 for CHB (Neptune Study)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04202653. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*